KLRS

NASDAQ

Kalaris Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)IPO2020

$6.14+0.05 (+0.90%)

News25/Ratings7

Price$6.14-3.70 (-37.60%)

2026-01-212026-04-24

News · 26 weeks37-33%

2025-11-022026-04-26

Mix2490d

SEC Filings14(58%)
Insider5(21%)
Other4(17%)
Analyst1(4%)

Latest news

25 items

1dSEC
SEC Form DEFA14A filed by Kalaris Therapeutics Inc.
DEFA14A - Kalaris Therapeutics, Inc. (0001754068) (Filer)
1dSEC
SEC Form DEF 14A filed by Kalaris Therapeutics Inc.
DEF 14A - Kalaris Therapeutics, Inc. (0001754068) (Filer)
9dANALYST
Morgan Stanley initiated coverage on Kalaris Therapeutics with a new price target
Morgan Stanley initiated coverage of Kalaris Therapeutics with a rating of Overweight and set a new price target of $14.00
11dSEC
SEC Form EFFECT filed by Kalaris Therapeutics Inc.
EFFECT - Kalaris Therapeutics, Inc. (0001754068) (Filer)
11dSEC
SEC Form EFFECT filed by Kalaris Therapeutics Inc.
EFFECT - Kalaris Therapeutics, Inc. (0001754068) (Filer)
12dSEC
SEC Form 424B3 filed by Kalaris Therapeutics Inc.
424B3 - Kalaris Therapeutics, Inc. (0001754068) (Filer)
12dSEC
SEC Form 424B3 filed by Kalaris Therapeutics Inc.
424B3 - Kalaris Therapeutics, Inc. (0001754068) (Filer)
15dSEC
SEC Form 8-K filed by Kalaris Therapeutics Inc.
8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
22dSEC
SEC Form S-3 filed by Kalaris Therapeutics Inc.
S-3 - Kalaris Therapeutics, Inc. (0001754068) (Filer)
22dSEC
SEC Form S-3 filed by Kalaris Therapeutics Inc.
S-3 - Kalaris Therapeutics, Inc. (0001754068) (Filer)
33dINSIDER
SEC Form 4 filed by Hagen Brett R
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
36dSEC
SEC Form 144 filed by Kalaris Therapeutics Inc.
144 - Kalaris Therapeutics, Inc. (0001754068) (Subject)
36dINSIDER
SEC Form 4 filed by Oxtoby Andrew
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
36dINSIDER
SEC Form 4 filed by Gall Matthew
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
36dINSIDER
SEC Form 4 filed by Feinsod Matthew
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
39dSEC
SEC Form S-8 filed by Kalaris Therapeutics Inc.
S-8 - Kalaris Therapeutics, Inc. (0001754068) (Filer)
39dSEC
SEC Form 10-K filed by Kalaris Therapeutics Inc.
10-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
39dSEC
SEC Form 8-K filed by Kalaris Therapeutics Inc.
8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
39dPR
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027 Intend to initiate Phase 3 clinical trials by year-end 2027 Completed oversubscribed $50.0 million private placement in December 2025 $118.0 million in cash, cash equivalents and marketable securities as of December 31, 2025 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical stage biopharmaceutical company dedicated to the development and commercializat
47dSEC
SEC Form 8-K filed by Kalaris Therapeutics Inc.
8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
67dINSIDER
Director Akkaraju Srinivas bought $5,000,006 worth of shares (479,847 units at $10.42) (SEC Form 4)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
67dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Kalaris Therapeutics Inc.
SCHEDULE 13D/A - Kalaris Therapeutics, Inc. (0001754068) (Subject)
67dSEC
SEC Form SCHEDULE 13G filed by Kalaris Therapeutics Inc.
SCHEDULE 13G - Kalaris Therapeutics, Inc. (0001754068) (Subject)
87dPR
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its Phase 1 study of TH103 will be presented at the 49th Annual Meeting of the Macula Society, taking place February 25-28 in San Diego, California. TH103 is a novel investigational therapy engineered by VEGF scientific pioneer Dr. Napoleone Ferrara to achieve enhanced VEGF inhibition and increased intraocular retention. The presentation will include safety, tolerability, pharmacokinetics and early efficacy outcomes following intravitreal a
123dANALYST
Chardan Capital Markets initiated coverage on Kalaris Therapeutics with a new price target
Chardan Capital Markets initiated coverage of Kalaris Therapeutics with a rating of Buy and set a new price target of $19.00